Maverix Medical completed the acquisition of Cirrus Bio.

Maverix Medical, a dedicated lung cancer platform, completed the acquisition of Cirrus Bio, a company that develops and brings to market multiomic solutions for the diagnosis and management of diseases. Financial terms were not disclosed. "Lung cancer remains the largest cancer killer, by far. The only way to improve survival rates for this extremely aggressive disease is to catch it early and act decisively. This acquisition gives Maverix unparalleled technology, talent, and expertise in early cancer detection, and will serve as the foundation for a broader diagnostic portfolio with the potential to transform lung cancer care," Duke Rohlen, Maverix Medical Executive Chairman.